RxDoctor Payments Data

Amir Qureshi, MD

Interventional Pain Medicine · Little Rock, ARNPI 1609846435

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (53.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Nevro Corp. at 26.7% of the total.

$14,366in general payments, 2019–2025

Across 279 payments — averaging $51.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$4K
  • Nalu Medical, Inc.$4K
  • Spinefrontier, Inc.$2K
  • Spinal Simplicity, LLC$2K
  • Boston Scientific$1K
  • Stryker$531
  • plus $1K from 24 others

What the payments were for

  • Travel & lodging$5,36537%
  • Food & beverage$7,72354%
  • Education$1,2799%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,366 in reported general payments places this provider in the 85th percentile of 29 interventional pain medicine providers in Arkansas.

See all interventional pain medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$249,011
Medicare patients
482
Services billed
2,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen833$21,722
Pregabalin209$4,401
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen169$4,237
Gabapentin317$4,225
Oxycodone Hcl273$3,428
Morphine Sulfate ErMorphine Sulfate101$2,300
Fentanyl24$2,232
Tizanidine Hcl241$1,718
Lidocaine20$1,596
Celecoxib54$1,279
Morphine Sulfate60$1,214
Cyclobenzaprine Hcl141$915
Amitriptyline Hcl92$790
Methocarbamol49$654
Methadone Hcl49$587

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →